MEDBOT-B (02252) rose more than 3%, with a gain of 2.87% at the time of writing to HK$28.68, and a turnover of HK$9.9557 million. The positive movement follows a recent research report from UBS, which expressed optimism about the company's robust overseas sales potential. MEDBOT-B reported that its overseas revenue surged 287% year-on-year last year, with sales of its Toumai surgical robot increasing more than fivefold. Unlike developed markets, MEDBOT-B focuses on middle-income developing regions such as South America, South Asia, and Central and Eastern Europe, where surgical robot penetration rates are currently low, indicating substantial demand. It is projected that by 2034, these regions will have a cumulative need for over 10,000 laparoscopic surgical robot installations. As one of the market pioneers, MEDBOT-B is expected to capture a 25% market share. UBS further noted that MEDBOT-B aims to double its total revenue by 2026 compared to 2025, with the proportion of overseas revenue anticipated to rise from 73% last year to over 80%. This growth is expected to help the company achieve breakeven in the first half of 2026.